Lyophilization USA Conference 2017

SMi Group16 - 17 November 2017, Iselin, USA.
As biopharmaceuticals continue to dominate the market the need for greater shelf life and protein stability has increased. For many biological products lyophilization is a necessity and the technology is constantly advancing. As manufacturing demands increase the global lyophilization market for pharmaceutical and biotechnology products is expected to reach $2.66 billion by 2019 and this a trend that is likely to continue as we push the boundaries of biopharmaceutical formulation and transport.

One of the main challenges in pharmaceutical lyophilization continues to be the scale- up and the implementation of QbD protocols for the optimization of cycles. Several companies are researching and developing ways to facilitate commercial bulk lyophilisation of vaccines, protein and cells while also reducing costs.

Lyophilization USA will gather leading experts from top pharma companies to discuss the latest cutting-edge developments in freeze drying, as well as solutions to on-going industry challenges.

Key Topics Addressed:

  • The impact of controlled nucleation on product quality and the technology being used for controlled ice nucleation.
  • Examining the development and scale up of a freeze-drying cycle for biotherapeutics.
  • Highlighting the approaches to effective holistic packaging and innovative design.

Featured Speakers:

  • Lokesh Kumar, Associated Scientist, Genentech
  • Charlie Tang, Associate Director, Formulation Development, Regeneron Pharmaceuticals
  • Guido Schmitz, Global Head of Packaging & Technology Innovation, Bayer Consumer Care
  • Perceval Sondag, Principal Statistician, Arlenda
  • Eric Munson, Professor, Pharmaceutical Sciences, University of Kentucky
  • Kelly Forney Stevens, Drug Product Development, GSK Vaccines
  • Melissa Lash, Scientist, Large Molecule Drug Development, Johnson & Johnson

For further information and to register, please visit:
http://www.smi-online.co.uk/pharmaceuticals/northamerica/Lyophilisation-USA

About SMi Group
The SMi Group is a highly Professional, Independent and Global company that specialises in the production of Business-to-Business Conferences, Workshops and Masterclasses. We research, create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical sectors.

We believe in bringing you the best events incorporating:

  • In-depth analysis of the subject matter
  • Tools, techniques and information to immediately benefit your business
  • High level contact with expert speakers
  • Insight into new areas, refreshing your knowledge
  • Opportunities to learn from key opinion leaders, and to engage through Q&A
  • Sessions with leading professionals and to network before, during and after event

Our management team has more than 70 years collective experience in the conference industry and our long-term success has been established by providing a reliable and expert service. This gives you the delegate, the confidence and reassurance, in knowing that we have brought you the best speakers and content for 20 years. The SMi management team plays a very active role in the day to day running of the business and events and we look forward to meeting you at an event soon!

Most Popular Now

Chemists characterize the fatal fungus among us

Life-threatening fungal infections affect more than two million people worldwide. Effective antifungal medications are very limited. Until now, one of the major challenge...

FDA approves first cancer drug through new oncolog…

The U.S. Food and Drug Administration today approved Kisqali (ribociclib) in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopa...

Discovery of kidney cancer driver could lead to ne…

University of North Carolina Lineberger Comprehensive Cancer Center scientists have uncovered a potential therapeutic target for kidney cancers that have a common genetic...

The immune system: T cells are built for speed

Without T cells, we could not survive. They are a key component of our immune system and have highly sensitive receptors on their surface that can detect pathogens. The e...

FDA approves first targeted treatment for patients…

The U.S. Food and Drug Administration today approved Tibsovo (ivosidenib) tablets for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (...

Women and older people under-represented in drug t…

Trying to determine how best to treat a patient, doctors often look to randomized clinical trials to guide their choice of what drug to prescribe. One of the most common ...

Novartis renews drug donation of Egaten® (triclabe…

Novartis reaffirms its commitment to the fight against liver fluke (fascioliasis), signing a renewed memorandum of understanding with the World Health Organization (WHO) ...

Pfizer initiates pivotal Phase 3 program for inves…

Pfizer Inc. (NYSE:PFE) and Spark Therapeutics (NASDAQ:ONCE) announced today that Pfizer initiated a Phase 3 open-label, multi-center, lead-in study (NCT03587116) to evalu...

Sanofi and REVOLUTION Medicines launch global part…

Sanofi and REVOLUTION Medicines, Inc. today announced an exclusive worldwide partnership to develop and commercialize targeted therapies, based on the biology of the cell...

Novartis marks a new era for migraine patients wit…

Novartis announced today that the European Commission (EC) approved Aimovig® (erenumab) for the prevention of migraine in adults experiencing four or more migraine days p...

FDA grants Breakthrough Therapy Designation for Ro…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Tecentriq® (atezolizumab) i...

New findings suggest allergic responses may protec…

The components of the immune system that trigger allergic reactions may also help protect the skin against cancer, suggest new findings. The research, led by Imperial Col...